Literature DB >> 24080538

Practical considerations in the use of ultrabrief ECT in clinical practice.

Cherrie Galletly1, Patrick Clarke, Tom Paterson, Ashlee Rigby, Shane Gill.   

Abstract

OBJECTIVE: Electroconvulsive therapy (ECT) is the most effective treatment for major depression. Brief pulse width (BPW; pulse width, 1.0 m/s) ECT is often associated with cognitive impairment. Ultrabrief (UB; pulse width, 0.3 m/s) ECT is better tolerated and causes less cognitive impairment so has been introduced as an alternative. Previous research has shown that more treatments are needed with UB ECT; however, there has not been any previous research into the impact of prescribing UB ECT on length of stay.
METHODS: This study reports naturalistic data collected from 258 inpatients in a private psychiatric hospital for 2 years since the introduction of UB ECT. Clinician and self-rated scales of depression severity and hospital service data were used to evaluate the number of ECT treatments, length of stay, and efficacy.
RESULTS: Patients prescribed UB ECT had, on average, 10.9 treatments compared to 8.8 for BPW ECT. They also spent more time in hospital; 30.3 days from the first ECT treatment to discharge compared to 24.7 days for patients prescribed BPW ECT. Excluding patients who switched treatments, 54% of patients prescribed UB ECT responded compared to 66.7% of patients prescribed BPW ECT. More patients (n = 42) switched from UB to BPW than from BPW to UB (n = 3). In the 4 years since the introduction of UB ECT, the number of patients prescribed ECT has increased, and the mean number of treatments per patient (for all patients receiving ECT) has increased from 7.7 to 11.6.
CONCLUSIONS: Ultrabrief ECT has significant advantages, reflected in the increased use of ECT since UB ECT became available. However, the greater number of treatments and the increased length of stay have important implications for service delivery, costs, and bed accessibility.

Entities:  

Mesh:

Year:  2014        PMID: 24080538     DOI: 10.1097/YCT.0000000000000081

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  5 in total

1.  The benefits and costs of changing treatment technique in electroconvulsive therapy due to insufficient improvement of a major depressive episode.

Authors:  Harold A Sackeim; Joan Prudic; D P Devanand; Mitchell S Nobler; Roger F Haskett; Benoit H Mulsant; Peter B Rosenquist; William V McCall
Journal:  Brain Stimul       Date:  2020-06-22       Impact factor: 8.955

2.  A two-site, open-label, non-randomized trial comparing Focal Electrically-Administered Seizure Therapy (FEAST) and right unilateral ultrabrief pulse electroconvulsive therapy (RUL-UBP ECT).

Authors:  Gregory L Sahlem; William V McCall; E Baron Short; Peter B Rosenquist; James B Fox; Nagy A Youssef; Andrew J Manett; Suzanne E Kerns; Morgan M Dancy; Laryssa McCloud; Mark S George; Harold A Sackeim
Journal:  Brain Stimul       Date:  2020-07-29       Impact factor: 8.955

3.  Duration of Treatment in Electroconvulsive Therapy Among Patients Beginning With Acute Course Right Unilateral Brief Pulse Stimuli.

Authors:  James Luccarelli; Thomas H McCoy; Alec P Shannon; Brent P Forester; Stephen J Seiner; Michael E Henry
Journal:  J ECT       Date:  2021-12-01       Impact factor: 3.692

4.  A randomized controlled trial of brief and ultrabrief pulse right unilateral electroconvulsive therapy.

Authors:  Colleen K Loo; Natalie Katalinic; Deirdre J Smith; Anna Ingram; Nathan Dowling; Donel Martin; Kerryn Addison; Dusan Hadzi-Pavlovic; Brett Simpson; Isaac Schweitzer
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-05       Impact factor: 5.176

5.  Rate of continuing acute course treatment using right unilateral ultrabrief pulse electroconvulsive therapy at a large academic medical center.

Authors:  James Luccarelli; Thomas H McCoy; Alec P Shannon; Brent P Forester; Stephen J Seiner; Michael E Henry
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-11-16       Impact factor: 5.270

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.